Released May 7, 2021, before the open
10-Q filed May 7, 2021, 37 days after period end · 0001628280-21-009446
Q1 2021 · 10-Q
Revenue—
Net Income-$2.16M-$2.16M N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.01-$0.01 N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$1,737,262N/M
Operating Cash Flow-$1,348,088N/M
Free Cash Flowderived-$1,358,784N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Net Income | -$2.16M | -$2.34M | -$14.77M | -$8.21M |
| EPS Diluted | -$0.01 | -$0.01 | -$0.11 | -$0.09 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR